Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
BioInvent International is a Swedish clinical-stage immunotherapy company focused on developing antibody-based cancer treatments using its proprietary F.I.R.S.T and n-CoDeR technology platforms. The company operates primarily through partnered programs with pharmaceutical companies and proprietary pipeline development, with lead assets including BI-1206 (anti-FcγRIIB) in Phase I/II trials for hematological malignancies and solid tumors. As a pre-revenue biotech, the stock trades on clinical trial milestones, partnership announcements, and cash runway visibility.
BioInvent monetizes its antibody discovery platforms through upfront licensing fees, development milestone payments, and future royalty streams from pharmaceutical partners. The company's F.I.R.S.T platform enables rapid identification of fully human antibodies, while n-CoDeR technology generates novel antibody formats. Current negative margins (-1054% operating margin) reflect typical pre-revenue biotech economics where R&D spending significantly exceeds partnership income. The business model depends on advancing proprietary assets (BI-1206, BI-1808) through clinical trials to inflection points that trigger partnership deals or eventual commercialization, with typical deal structures providing $50-200M in potential milestones plus mid-to-high single-digit royalties.
Clinical trial data readouts for BI-1206 in non-Hodgkin lymphoma and multiple myeloma (Phase I/II interim analyses)
Partnership announcements or milestone payments from existing collaborations (Transgene, historical BMS relationship)
Cash runway updates and financing events (equity raises, non-dilutive funding) given $0.4B annual cash burn
Regulatory interactions including IND filings for new programs or Fast Track/Orphan Drug designations
Competitive landscape shifts in anti-FcγRIIB and tumor microenvironment modulation space
Clinical trial failure risk inherent to early-stage oncology programs with BI-1206 and BI-1808 still in Phase I/II, where historical industry success rates are 10-15% from Phase I to approval
Regulatory pathway uncertainty for novel mechanisms like FcγRIIB antagonism where limited precedent exists for approval standards and required evidence packages
Competitive intensity in immuno-oncology with 3,000+ programs globally and potential for mechanism obsolescence if CAR-T, ADCs, or other modalities dominate treatment paradigms
Larger biotechs (Genmab, BioNTech) and pharma companies developing competing tumor microenvironment modulators with superior resources for trial execution and commercialization
Platform technology risk as antibody discovery capabilities become commoditized through AI-driven design tools and contract research organizations offering similar services
Cash runway pressure with $0.4B annual burn and pre-revenue status requiring equity financing within 12-18 months absent partnership influx, risking significant dilution at depressed valuations (stock down 30.5% over 6 months)
Partnership dependency where loss of key collaboration or milestone payment delays could accelerate financing needs and compress strategic optionality
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as trial timelines and regulatory processes follow scientific rather than economic cycles. However, partnership activity and financing availability show moderate correlation to risk appetite in broader markets. Pharmaceutical partner budgets for business development remain relatively stable through cycles given long-term portfolio planning horizons.
Rising rates create moderate headwinds through two channels: (1) higher discount rates compress NPV of distant cash flows from potential drug approvals 5-10 years out, disproportionately impacting pre-revenue biotech valuations, and (2) reduced risk appetite makes equity financing more dilutive and expensive. The company's 7.40x current ratio provides cushion, but eventual need for capital raises makes rate environment relevant. Minimal direct impact from financing costs given 0.02x debt/equity ratio.
Minimal direct credit exposure as the company carries negligible debt and operates on equity capital. Indirect exposure exists through pharmaceutical partner financial health affecting milestone payment reliability and through venture capital/biotech IPO market conditions influencing future financing availability.
growth - Attracts high-risk tolerance biotech specialists and venture-style public market investors seeking asymmetric returns from clinical inflection points. The -960.9% net margin and binary outcome profile (drug approval vs. failure) appeals to investors comfortable with 50-80% downside risk for potential 300-500% upside on positive trial data. Not suitable for value or income investors given negative cash flows and no dividend potential. Recent 12% one-year return despite 30.5% six-month decline reflects high volatility around news flow.
high - Clinical-stage biotech stocks typically exhibit 60-100% annualized volatility with 20-40% single-day moves common around data releases. The $1.7B market cap and Swedish listing (lower liquidity than US exchanges) amplify volatility. Stock performance shows characteristic biotech pattern: -16.5% over three months, -30.5% over six months, but +12% over one year, reflecting episodic news-driven trading.
